(BCAT) BlackRock Capital - Ratings and Ratios
Bonds, Stocks, Alternatives
BCAT EPS (Earnings per Share)
BCAT Revenue
Description: BCAT BlackRock Capital
BlackRock Capital Allocation Trust (BCAT) is a closed-end investment company listed on the NYSE, operating within the Asset Management & Custody Banks sub-industry. Its primary objective is to provide shareholders with a high level of income and capital appreciation.
The trusts performance is closely tied to the overall health of the financial markets, particularly the asset management sector. Key economic drivers influencing BCATs performance include interest rates, market volatility, and the overall demand for asset management services. The trusts ability to generate income is also affected by the dividend yield of its underlying investments.
To evaluate BCATs performance, key performance indicators (KPIs) such as the distribution yield, net asset value (NAV) return, and the trusts expense ratio are crucial. A high distribution yield indicates a strong income generation capability, while a stable NAV return suggests effective investment management. A low expense ratio is also desirable as it maximizes the returns to shareholders.
The asset management industry is highly competitive, with firms like BlackRock, Vanguard, and State Street Global Advisors dominating the market. BCATs ability to compete effectively is influenced by its investment strategy, the expertise of its management team, and its ability to adapt to changing market conditions.
From a financial perspective, BCATs market capitalization and price-to-earnings (P/E) ratio are important metrics. A relatively low P/E ratio may indicate undervaluation, presenting a potential buying opportunity. The trusts return on equity (RoE) is also a critical metric, as it measures the return generated on shareholders equity.
BCAT Stock Overview
| Market Cap in USD | 1,550m |
| Sub-Industry | Asset Management & Custody Banks |
| IPO / Inception | 2020-09-25 |
BCAT Stock Ratings
| Growth Rating | 41.7% |
| Fundamental | 51.2% |
| Dividend Rating | 94.3% |
| Return 12m vs S&P 500 | -2.32% |
| Analyst Rating | - |
BCAT Dividends
| Dividend Yield 12m | 23.77% |
| Yield on Cost 5y | 29.86% |
| Annual Growth 5y | 91.11% |
| Payout Consistency | 82.5% |
| Payout Ratio | 153.5% |
BCAT Growth Ratios
| Growth Correlation 3m | 85.8% |
| Growth Correlation 12m | 67.4% |
| Growth Correlation 5y | 35.7% |
| CAGR 5y | 5.77% |
| CAGR/Max DD 5y | 0.16 |
| Sharpe Ratio 12m | 0.87 |
| Alpha | 4.94 |
| Beta | 0.499 |
| Volatility | 11.24% |
| Current Volume | 679.3k |
| Average Volume 20d | 551.5k |
| Stop Loss | 14.5 (-3.5%) |
| Signal | 1.06 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (194.4m TTM) > 0 and > 6% of Revenue (6% = 11.9m TTM) |
| FCFTA 0.18 (>2.0%) and ΔFCFTA 10.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.18 (>3.0%) and CFO 354.9m > Net Income 194.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| error: Current Ratio cannot be calculated (needs Total Current Assets and Liabilities) |
| Outstanding Shares last Quarter (NaN) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 98.35% (prev 0.0%; Δ 98.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 9.46% (prev 9.18%; Δ 0.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.0 (EBITDA TTM 0.0 / Interest Expense TTM 1.40m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 51.21
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 22.99% = 5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda data missing |
| 6. ROIC - WACC 0.0% = 0.0 |
| 7. RoE 10.60% = 0.88 |
| 8. Revenue Trend data missing |
| 9. Revenue CAGR data missing |
| 10. EPS Trend -46.77% = -1.17 |
| 11. EPS CAGR -94.86% = -2.50 |
What is the price of BCAT shares?
Over the past week, the price has changed by +1.42%, over one month by +2.03%, over three months by +7.35% and over the past year by +14.25%.
Is BlackRock Capital a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCAT is around 19.91 USD . This means that BCAT is currently undervalued and has a potential upside of +32.47% (Margin of Safety).
Is BCAT a buy, sell or hold?
What are the forecasts/targets for the BCAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 22.1 | 46.8% |
Last update: 2025-08-28 04:33
BCAT Fundamental Data Overview
CCE Cash And Equivalents = 6.30m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 8.082
P/S = 7.9489
P/B = 0.9003
Beta = None
Revenue TTM = 197.7m USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -6.30m USD (from netDebt column, last quarter)
Enterprise Value = 1.54b USD (1.55b + (null Debt) - CCE 6.30m)
Interest Coverage Ratio = 0.0 (Ebit TTM 0.0 / Interest Expense TTM 1.40m)
FCF Yield = 22.99% (FCF TTM 354.9m / Enterprise Value 1.54b)
FCF Margin = 179.5% (FCF TTM 354.9m / Revenue TTM 197.7m)
Net Margin = 98.35% (Net Income TTM 194.4m / Revenue TTM 197.7m)
Gross Margin = 98.35% ((Revenue TTM 197.7m - Cost of Revenue TTM 3.25m) / Revenue TTM)
Tobins Q-Ratio = 0.90 (Enterprise Value 1.54b / Book Value Of Equity 1.72b)
Interest Expense / Debt = unknown (Interest Expense 1.40m / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets 6.30m / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt -6.30m / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 354.9m)
Total Stockholder Equity = 1.83b (last 4 quarters mean)
RoA = 10.10% (Net Income 194.4m, Total Assets 1.92b )
RoE = 10.60% (Net Income TTM 194.4m / Total Stockholder Equity 1.83b)
RoCE = unknown (Ebit 0.0 / (Equity 1.83b + L.T.Debt none))
RoIC = 0.0% (NOPAT 0.0 / Invested Capital 1.87b)
WACC = unknown (E(1.55b)/V(0.0) * Re(7.85%)) + (D(none)/V(0.0) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 5.10 | Cagr: 1.82%
Discount Rate = 7.85% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈285.5m ; Y1≈352.2m ; Y5≈600.8m
Fair Price DCF = 97.53 (DCF Value 10.22b / Shares Outstanding 104.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -46.77 | EPS CAGR: -94.86%
EPS Growth-of-Growth: N/A
Additional Sources for BCAT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle